Report Library
All Reports
Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest
February 04, 2019
A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic
area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered,
with a focus on SGLT-2 inhibitors.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
| Indications Covered: | Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) |
Additional Resources: